Literature DB >> 2821074

Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage.

T R Martin1, G Raugi, T L Merritt, W R Henderson.   

Abstract

Human alveolar macrophages release chemotactic activity for neutrophils, providing a role for alveolar macrophages in regulating inflammation in the lung. As alveolar macrophages produce large amounts of leukotriene B4 (LTB4), a chemotactically active lipoxygenase product of arachidonic acid, we investigated the contribution of LTB4 to the total neutrophil chemotactic activity produced by these cells. Normal human alveolar macrophages were recovered by bronchoalveolar lavage from healthy volunteers and incubated either with the calcium ionophore A23187 for 1 h, or with opsonized zymosan particles or latex beads for 3 h. Nordihydroguaretic acid (NDGA), a relatively specific lipoxygenase inhibitor, blocked the release of neutrophil chemotactic activity after all three stimuli in a dose-dependent manner. This correlated with blockade of LTB4 production as measured by high performance liquid chromatography using freshly isolated alveolar macrophages, as well as blockade of [3H]LTB4 production by macrophages prelabeled with [3H]arachidonate. Molecular sieve chromatography using Sephadex G-50 confirmed that essentially all of the chemotactic activity in the stimulated macrophage supernatants co-eluted with authentic [3H]LTB4, and that NDGA completely blocked the chemotactic activity in the eluting fractions. Readdition of authentic LTB4 (1 X 10(-7) M) to the NDGA-blocked macrophage supernatants restored the chemotactic activity in the supernatants. The macrophage supernatants did not contain platelet-activating factor-like activity, as measured by the stimulation of [3H]serotonin release from rabbit platelets, and by high performance liquid chromatography. NDGA did not change the protein-secretion profiles of fresh alveolar macrophages, or of macrophages prelabeled with [35S]methionine. The complement (C) components C5adesarg were not detected in any of the supernatants by radioimmunoassay. Concentration of the supernatants by positive pressure filtration (5,000-D membrane) did not augment chemotactic activity in the stimulated supernatants or uncover chemotactic activity in the NDGA-blocked supernatants. As with the 3-h studies, when alveolar macrophages were incubated overnight with opsonized zymosan, all of the increase in chemotactic activity could also be blocked by NDGA. These data indicate that LTB4 is the predominant neutrophil chemotactic factor secreted by the normal resident human alveolar macrophage in response to two major types of stimuli, calcium fluxes across the cell membrane and the phagocytosis of opsonized particulates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821074      PMCID: PMC442354          DOI: 10.1172/JCI113168

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  A macrophage receptor for (mannose/glucosamine)-glycoproteins of potential importance in phagocytic activity.

Authors:  G A Warr
Journal:  Biochem Biophys Res Commun       Date:  1980-04-14       Impact factor: 3.575

2.  Alveolar macrophage lipoxygenase products of arachidonic acid: isolation and recognition as the predominant constituents of the neutrophil chemotactic activity elaborated by alveolar macrophages.

Authors:  F H Valone; M Franklin; F F Sun; E J Goetzl
Journal:  Cell Immunol       Date:  1980-09-01       Impact factor: 4.868

3.  The macrophage as an effector cell.

Authors:  C F Nathan; H W Murray; Z A Cohn
Journal:  N Engl J Med       Date:  1980-09-11       Impact factor: 91.245

4.  A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration.

Authors:  W Falk; R H Goodwin; E J Leonard
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

5.  Regulation of the release of alveolar macrophage-derived neutrophil chemotactic factor.

Authors:  J E Gadek; G W Hunninghake; R L Zimmerman; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1980-04

6.  Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization.

Authors:  W W Merrill; G P Naegel; R A Matthay; H Y Reynolds
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

7.  Human neutrophil-derived platelet activating factor.

Authors:  G Z Lotner; J M Lynch; S J Betz; P M Henson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

8.  Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents.

Authors:  E J Goetzl; C K Derian; A I Tauber; F H Valone
Journal:  Biochem Biophys Res Commun       Date:  1980-06-16       Impact factor: 3.575

9.  Monohydroxyeicosatetraenoic acids (HETEs) induce degranulation of human neutrophils.

Authors:  W F Stenson; C W Parker
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

10.  Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization.

Authors:  G W Hunninghake; J E Gadek; H M Fales; R G Crystal
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

View more
  17 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.

Authors:  R H Lawrence; T C Sorrelli
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

4.  Release of prostaglandin E2 and leukotriene B4 by alveolar macrophages from patients with sarcoidosis.

Authors:  V De Rose; L Trentin; M T Crivellari; A Cipriani; G Gialdroni Grassi; E Pozzi; G Folco; G Semenzato
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

5.  Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  J Wilborn; M Bailie; M Coffey; M Burdick; R Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

6.  In vitro human polymorphonuclear leukocyte chemokinesis and human monocyte chemotaxis are different activities of aminoterminal and carboxyterminal substance P.

Authors:  C J Wiedermann; F J Wiedermann; A Apperl; G Kieselbach; G Konwalinka; H Braunsteiner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-08       Impact factor: 3.000

7.  Stimulus-specific production of cyclooxygenase and lipoxygenase metabolites of arachidonic acid by bovine alveolar macrophages.

Authors:  W W Laegreid; S M Taylor; M D Englen; K M Straub; R M Silflow; H D Liggitt; R W Leid
Journal:  Inflammation       Date:  1989-04       Impact factor: 4.092

8.  Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.

Authors:  T R Martin; B P Pistorese; E Y Chi; R B Goodman; M A Matthay
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

9.  Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages.

Authors:  R C Hubbard; G Fells; J Gadek; S Pacholok; J Humes; R G Crystal
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs.

Authors:  T R Martin; J C Mathison; P S Tobias; D J Letúrcq; A M Moriarty; R J Maunder; R J Ulevitch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.